Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 31, 2013Antimicrobial Agents and ChemotherapyOpen Access

New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World

View Full Paper
Ask AI
Bookmark
Share

Authors

SDSarah M. DrawzUniversity of MinnesotaKPKrisztina M. Papp‐WallaceNortheast Health
Robert A. Bonomo
Robert A. BonomoRutgers, The State University of New Jersey

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Drawz et al. (2013) studied this question.

synapsesocial.com/papers/6a705cf2f44fa9f079ddfc05https://doi.org/10.1128/aac.00826-13
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New Delhi Metallo-β-Lactamase: Structural Insights into β-Lactam Recognition and Inhibition2012 · 293 citations
  2. 2Three Decades of β-Lactamase Inhibitors2010 · 1,686 citations
  3. 3Structural basis for the broad-spectrum inhibition of metallo-β-lactamases by thiols2008 · 125 citations
  4. 4Exploring sequence requirements for C<sub>3</sub>/C<sub>4</sub> carboxylate recognition in the <i>Pseudomonas aeruginosa</i> cephalosporinase: Insights into plasticity of the AmpC β‐lactamase2011 · 47 citations